Anjali Singh

Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

Higher capacity utilisation, operating leverage and broad-based demand across CDMO, hospital generics and consumer healthcare are expected to support margins in FY27

As uncertainty becomes the new normal, M&M must enter attack mode: Mahindra

Mahindra Group chairman says prolonged global uncertainty offers prepared companies an edge, with India poised to emerge as a multi-aligned 'connector economy'

ChrysCapital acquires Novartis India, appoints Vikas Gupta as CEO

The private equity firm has taken control of the BSE-listed drugmaker, appointed Vikas Gupta as CEO and plans to build a branded generics platform in India

Sun Pharma to launch semaglutide in Brazil with Hypera Pharma soon

Sun Pharma will launch the once-weekly diabetes treatment through Hypera Pharma as generic competition intensifies in Brazil's $413 million semaglutide market

L&T bets ₹5,000 crore to become Tier-1 supplier in auto electronics market

Engineering major will invest over five years in EV motors, ADAS and connected-vehicle technologies, targeting a fast-growing market dominated by global players

JLR India posts record Q1 retail sales on strong luxury SUV demand

The company retailed 1,665 vehicles in Q1 FY27, up 11 per cent year-on-year, with the Range Rover, Range Rover Sport and Defender accounting for over 85 per cent of sales

Tata Motors' Gujarat plant hit by floods; Nexon, Sierra output disrupted

Flooding in Gujarat disrupts operations at Tata Motors' Sanand plant and supplier facilities, with production of key passenger vehicle models affected

Ramkrishna Forgings Q1 profit nearly quadruples; plans ₹170 crore capex

Forging company reports a 298 per cent jump in quarterly profit on higher revenue and margins, while approving ₹170 crore capex to expand passenger vehicle components business

Hero to TVS: Two-wheeler makers ride export wave, but watch road ahead

Hero, TVS, and Bajaj count on overseas markets while bracing for global uncertainty

Manipal IPO to be India's biggest in healthcare, seeks to raise ₹9,275 cr

₹9,275-crore issue opens on July 29 as the Temasek-backed hospital chain plans to add around 3,000 beds through greenfield and brownfield projects

Cipla's Q1 net falls 39% on US business; maintains FY27 margin guidance

The drugmaker attributed the decline to a high base in North America, retained its FY27 Ebitda margin guidance and expects new product launches to support growth

Mercedes-Benz India sees strong festive demand; new CLA sold out for 2026

The luxury carmaker expects 2026 to be its best-ever year, supported by robust order books, sustained demand across segments and strong festive-season momentum

Dr Reddy's Labs Q1FY27 results: Net profit plunges 69% to ₹443 crore

The drugmaker attributed the sharp earnings decline to a one-time semaglutide provision and the end of its lenalidomide agreement, while retaining its FY27 guidance

TVS Motor sees international biz maintaining growth momentum in FY27

Chairman Sudarshan Venu says overseas operations now contribute over a quarter of revenue as the company expands across Africa, Latin America, Asia and Europe

TVS Motor net profit zooms 67% to ₹1,019.4 crore, revenues up 33.5%

Revenue rose 34 per cent as TVS Motor posted record quarterly sales, with management expecting double-digit industry growth to continue on strong exports and EV demand

Takeda gets DCGI approval for QDENGA, India's first dengue vaccine

The vaccine has been approved for individuals aged 4-60 years and can be administered without prior dengue screening, marking India's first vaccine-based strategy against the disease

Emcure broadens Poviztra's use for MASH after CDSCO nod for semaglutide

The drugmaker will market Poviztra for treating MASH after CDSCO approved the new indication for innovator semaglutide, expanding the medicine's approved uses in India

Divi's Labs MD's payout tops ₹100 cr on commissions, leads industry peers

Divi's Laboratories MD Murali K Divi topped India's pharma executive pay chart in FY26 with ₹100.26 crore, driven almost entirely by profit-linked commission

Smart cars' new crash test: Cybersecurity and customer data privacy

Transparency over customer data is becoming a core competitive advantage for brands

Strong H1 dispatches may propel passenger vehicles to record 2026

Robust utility vehicle demand, GST 2.0-led momentum and lower financing costs keep passenger vehicle dispatches strong, with industry expecting record sales in calendar 2026